Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Financial performance
Oncology
Innovation: Pipeline overview
Financial review
Conclusion
Appendix
Innovation: Clinical trials
20+ potential billion USD+ pipeline assets with approval by 2026
Most are supported by high strength of evidence
Selected assets
Unprobabilized
peak sales
USD bn / multi-bn
Strength of evidence
Moderate
Sabatolimab
MDS; AML
NIS793
PDAC; Colorectal Cancer
Pelacarsen
CVRR
Canakinumab
Adj. NSCLC
Ociperlimab¹
NSCLC
UNR844
Presbyopia
Libvatrep (SAF312)
Chronic Ocular Surface Pain
TNO155, JDQ443²
NSCLC; Colorectal Cancer;
Combos
Iptacopan
PNH; C3G; IgAN; aHUS
Remibrutinib
CSU; MS
Zolgensma
SMA IT
Ligelizumab
FA; CINDU
Strength of evidence
High
Kisqali
Adj. BC (+endocrine th.)
YTB3231
2L DLBCL
lanalumab
Sjogren's; SLE; AIH;
Lupus Nephritis
Ensovibep
Coronavirus infection
Leqvio
Hypercholesterolemia
Cosentyx
Multiple indications
177 Lu-PSMA-617
mCRPC post & pre-taxane;
MHSPC
Scemblix
3L+ CML; 1L CML
Tislelizumab
Multiple indications
Piqray (alpelisib)
PROS; HER2+ adv BC;
TNBC; ovarian cancer
Most advanced and
key indication(s)
approved by 2026
Submission
Phase III
Phase II
LCM
✓ Approved
Unprobabilized
peak sales
up to USD 1bn
1. BeiGene option deal.
Lutathera
1L G2/G3 NET
Kymriah
r/r Follicular Lymphoma
Tafinlar/Mekinist
Solid Tumor Agnostic
Beovu
DME
Jakavi
SR GvHD
2. Ph3 to start in 2022. Assets are shown in the phase of the most advanced indication (listed first). Value based on the total of the listed indication(s).
indication: High if in Ph3 or when Ph2 results available for the same MoA in the lead indication.
Strength of evidence based on the most advanced
55 Investor Relations | Q4 2021 Results
U NOVARTIS | Reimagining MedicineView entire presentation